Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

94 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Germline Variants in Patients Affected by Both Uveal and Cutaneous Melanoma.
Johansson PA, Palmer JM, McGrath L, Warrier S, Hamilton HR, Beckman T, D'Mellow MG, Brooks KM, Glasson W, Hayward NK, Pritchard AL. Johansson PA, et al. Among authors: brooks km. Pigment Cell Melanoma Res. 2025 Jan;38(1):e13199. doi: 10.1111/pcmr.13199. Epub 2024 Sep 24. Pigment Cell Melanoma Res. 2025. PMID: 39315505 Free PMC article.
Iris melanoma in an Australian cohort.
McGrath LA, Warrier SK, Glasson WJ, D'Mellow MG, Hamilton HR, Palmer JM, Brooks KM, Johansson PA, Hayward NK. McGrath LA, et al. Among authors: brooks km. Clin Exp Ophthalmol. 2024 Nov;52(8):880-887. doi: 10.1111/ceo.14424. Epub 2024 Jul 24. Clin Exp Ophthalmol. 2024. PMID: 39048918
Pharmacokinetics and Safety of Remdesivir in Pregnant and Nonpregnant Women With COVID-19: Results From IMPAACT 2032.
Brooks KM, Baltrusaitis K, Clarke DF, Nachman S, Jao J, Purswani MU, Agwu A, Beneri C, Deville JG, Powis KM, Stek AM, Eke AC, Shapiro DE, Capparelli E, Greene E, George K, Yin DE, Jean-Philippe P, Chakhtoura N, Bone F, Bacon K, Johnston B, Reding C, Kersey K, Humeniuk R, Best BM, Mirochnick M, Momper JD; IMPAACT 2032 Study Team. Brooks KM, et al. J Infect Dis. 2024 Oct 16;230(4):878-888. doi: 10.1093/infdis/jiae298. J Infect Dis. 2024. PMID: 38839047 Clinical Trial.
Tigilanol tiglate is an oncolytic small molecule that induces immunogenic cell death and enhances the response of both target and non-injected tumors to immune checkpoint blockade.
Cullen JK, Yap PY, Ferguson B, Bruce ZC, Koyama M, Handoko H, Hendrawan K, Simmons JL, Brooks KM, Johns J, Wilson ES, de Souza MMA, Broit N, Stewart P, Shelley D, McMahon T, Ogbourne SM, Nguyen TH, Lim YC, Pagani A, Appendino G, Gordon VA, Reddell PW, Boyle GM, Parsons PG. Cullen JK, et al. Among authors: brooks km. J Immunother Cancer. 2024 Apr 24;12(4):e006602. doi: 10.1136/jitc-2022-006602. J Immunother Cancer. 2024. PMID: 38658031 Free PMC article.
94 results